Advertisement
News
Subscribe to MDT Magazine News

Peptimmune Inc. files for Chapter 7

March 23, 2011 10:33 am | by Mass High Tech: The Journal of New England Technology | Comments

Peptimune Inc., a privately held biotechnology company in Cambrige, has filed under Chapter 7 of the bankruptcy code, after failing to raise a proposed $35 million round of venture capital funding.

ACT wins patent in China for stem cell manufacturing technique

March 23, 2011 10:33 am | by Mass High Tech: The Journal of New England Technology | Comments

Advanced Cell Technology Inc. has secured patent protection in China for its process of making and preparing retinal pigment epithelial cells from human stem cells for use in treating macular degenerative diseases.

CVS/pharmacy Debuts the "To Your Health" Program in Los Angeles Bringing 240 Free Health Screening Events to the Community

March 23, 2011 10:32 am | by Bio-Medicine.Org | Comments

LOS ANGELES, March 23, 2011 /- CVS/pharmacy, the nation's leading retail pharmacy, brings its "To Your Health" free health screening program to Los Angeles, Calif. on Saturday, March 26. The program will provide free preventive health screenings for Los Angeles area residents at 240...

TOPICS:
Advertisement

Creating a Grid for STEM Education and Advanced Manufacturing Careers

March 23, 2011 8:39 am | by Society of Manufacturing Engineers | Comments

DEARBORN, Mich., March 21, 2011 — Steady growth and measured funding of more than $5 million in five years to create a STEM grid supporting advanced manufacturing education is being realized by the SME Education Foundation and its partner, Project Lead The Way (PLTW). Simple and...

The Automation Federation and SME Education Foundation Sign Memorandum of Membership

March 23, 2011 8:39 am | by Society of Manufacturing Engineers | Comments

RESEARCH TRIANGLE PARK, N. C., DEARBORN, Mich., March 21, 2011 — The Automation Federation (AF) announced that, earlier this month, the SME Education Foundation has become one of the newest members of AF. More

Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Ovarian Adnexal Mass Assessment Score Test System

March 23, 2011 8:30 am | by U.S. Food & Drug Administration | Comments

This document was developed as a special controls guidance to support the classification of ovarian adnexal mass assessment score test system into class II (special controls). An ovarian adnexal mass assessment score test system measures one or more...

TOPICS:

Maryland gov delays action on $2.4B drug contract

March 23, 2011 7:45 am | by TOM LoBIANCO - Associated Press - Associated Press | Comments

Maryland Gov. Martin O'Malley delayed action on a $2.4 billion prescription drug contract Tuesday, saying a challenge to the deal should be resolved first.The Board of Public Works was scheduled to decide Wednesday whether Express Scripts Inc. should win the five-year deal to provide...

Southeast Texas Medical Associates Building Strong Post Treatment Care Programs with IBM Business Analytics Software

March 23, 2011 7:31 am | by IBM | Comments

IBM today announced that Southeast Texas Medical Associates (SETMA), is using IBM business analytics software to gain greater insight into hospital readmissions and data that will help identify causes and design interventions to prevent patients from having to return to the hospital soon...

Advertisement

Polar Partners with 'Shedding for the Wedding' Trainer and NGRâ„¢ President and CEO Jennifer Cohen

March 23, 2011 7:31 am | by Bio-Medicine.Org | Comments

LAKE SUCCESS, N.Y., March 23, 2011 /- Polar ( www.polarusa.com ), the leader in heart rate monitoring and fitness assessment technology, today announced a partnership with celebrity fitness trainer and health authority Jennifer Cohen .  Polar selected Cohen, president and CEO of...

TOPICS:

Gilead HIV drug meets study goal

March 23, 2011 6:45 am | by The Associated Press | Comments

Gilead Sciences Inc. said Wednesday its potential HIV treatment elvitegravir met its key goals in a late-stage study.Its shares rose 41 cents to $40.85 in morning trading.Patients received once-daily doses of the drug candidate over a 48-week period or a twice daily dose of raltegravir, which...

Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeich's Genousâ„¢ Stent in Diabetic Patients

March 23, 2011 5:34 am | by Bio-Medicine.Org | Comments

HONG KONG, March 23, 2011 /- OrbusNeich today announced that 12-month outcomes data from a subset analysis of the global e-HEALING registry were published online ahead of print in the Journal of Interventional Cardiology and demonstrated the effectiveness and safety of the company's...

TOPICS:

Poll: Do You Use Twitter?

March 23, 2011 5:33 am | by Diagnostic Imaging | Comments

Twitter's popularity continues to grow, and hundreds of physicians are turning to the 140-character platform to connect and share information. Do you tweet?

TOPICS:

Are Your Managed Care Agreements Performing?

March 23, 2011 5:32 am | by Diagnostic Imaging | Comments

As providers continue to wrestle with both the planned and unknown annual reductions in reimbursement, it is critically important to understand the managed care component of your payer mix - and more importantly, to understand if each contract is delivering its intended benefit(s).

TOPICS:

PRA International Experts to Speak at Industry Events

March 23, 2011 5:32 am | by Bio-Medicine.Org | Comments

RALEIGH, N.C., March 23, 2011 /- PRA International, a leading Clinical Research Organization, announces that two of our experts will be speakers at the upcoming Partnerships in Clinical Trials and Late Phase Drug Development conferences. PRA will also be exhibiting at both conferences....

TOPICS:

Huifeng Bio-Pharmaceutical Technology Announces New Senior Vice President of Finance

March 23, 2011 4:33 am | by Bio-Medicine.Org | Comments

XI'AN, China, March 23, 2011 /PRNewswire-Asia-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB ) ("Huifeng" or "the Company"), specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives,...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading